Koneqia Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. The company leverages its proprietary brain access platform to enable delivery of therapeutic molecules across the [blood-brain barrier](/entities/blood-brain-barrier) (BBB)[@koneqia].
...
Koneqia Therapeutics
Overview
Mermaid diagram (expand to render)
Koneqia Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. The company leverages its proprietary brain access platform to enable delivery of therapeutic molecules across the [blood-brain barrier](/entities/blood-brain-barrier) (BBB)[@koneqia].
Founded in 2022 and headquartered in San Francisco, California, Koneqia aims to address the critical challenge of CNS drug delivery that has hindered the development of effective treatments for Alzheimer's and other neurological disorders.
Enhanced brain penetration of large molecule therapeutics
Receptor-mediated transcytosis optimization
Targeted delivery to specific brain cell types
Reduced peripheral exposure and side effects
The platform addresses a fundamental challenge in CNS drug development: the BBB prevents approximately 98% of small molecule drugs and virtually all large molecule therapeutics from reaching the brain in therapeutic concentrations[@bloodbrain2023].
[TREM2](/genes/trem2) Modulation
KQ-001 is a small molecule [TREM2](/genes/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) modulator designed to:
Enhance microglial function
Improve [Aβ](/proteins/amyloid-beta) clearance
Reduce neuroinflammation
Protect synaptic function
This approach differs from antibody-based [TREM2](/genes/trem2) agonists by offering potential for oral dosing and improved brain penetration.
Science
[TREM2](/genes/trem2) Biology in Alzheimer's
[TREM2](/genes/trem2) is a receptor expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) in the brain. Genetic variants in the [TREM2](/genes/trem2) gene significantly increase AD risk:
Koneqia's approach aims to develop small molecules that enhance [TREM2](/genes/trem2) signaling, potentially improving microglial function in AD patients[@trem2024].
ApoE4 Modification
The company's ApoE4 modifier program targets apolipoprotein E4, the strongest genetic risk factor for late-onset AD:
~40% of AD patients carry at least one ApoE4 allele
ApoE4 carriers have earlier onset and faster progression
Current approaches focus on enhancing ApoE4 function or reducing its pathological effects
Business Details
Headquarters: San Francisco, California, USA
Ticker: Private
Founded: 2022
Funding: Series A ($45M, 2023)
Investors: Leading neurodegenerative disease-focused VCs